<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331951</url>
  </required_header>
  <id_info>
    <org_study_id>RP016</org_study_id>
    <nct_id>NCT04331951</nct_id>
  </id_info>
  <brief_title>Sensitivity of Targeted Biopsy Within Sydney Protocol for GIM</brief_title>
  <official_title>Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for Extensive Gastric Intestinal Metaplasia Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sensitivity of Targeted Biopsy Within Sydney Protocol by Using Narrow Band Imaging for&#xD;
      Extensive Gastric Intestinal Metaplasia Diagnosis&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The aim of this study is to evaluate the sensitivity of targeted biopsy within Sydney&#xD;
      protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis&#xD;
&#xD;
      Research design: Diagnosis study&#xD;
&#xD;
      Sample size: 105 cases&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
      The outcomes will be presented using 2 by 2 tables and if the data are normal distribution&#xD;
      the categorical data will be analysed using McNemar's test&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale:&#xD;
&#xD;
      Gastric cancer has been in the top-5 of cancer-related death worldwide. Early detection by&#xD;
      screening program in high risk patients is very important. If we can detect pre-malignant&#xD;
      lesion eg. gastric intestinal metaplasia, we can provide the appropriate surveillance program&#xD;
      to those patients. However, the screening protocol for gastric intestinal metaplasia remained&#xD;
      unclear. Recently in July 2019, British Society of Gastroenterology published the guideline&#xD;
      on the diagnosis and management of patients at risk of gastric adenocarcinoma. The&#xD;
      image-enhanced endoscopy (IEE) is recommended as the best modality for assessing gastric&#xD;
      intestinal metaplasia. Additionally, they recommended taking biopsy by using Sydney protocol&#xD;
      which means taking biopsy at two areas for antrum, two areas for body and one for incisura&#xD;
      although they look normal. We aimed to evaluate the sensitivity of this protocol for&#xD;
      extensive gastric intestinal metaplasia (GIM) diagnosis in this study.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
        -  All patients with history of GIM will be enrolled and undergone standard with white&#xD;
           light esophagogastroduodenoscopy (EGD).&#xD;
&#xD;
        -  Those with suspected lesions of GIM will proceed to narrow band imaging (NBI)-mode&#xD;
           endoscopy.&#xD;
&#xD;
        -  Targeted biopsy will be done at the suspected GIM lesions. Random biopsy will be while&#xD;
           will be done if no suspicious GIM lesion seen.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      All data will be processed and recorded by one physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The pathologists will be blinded for the result of endoscopic finding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis</measure>
    <time_frame>4 weeks after completing the enrollment.</time_frame>
    <description>Sensitivity of targeted biopsy within Sydney protocol by using narrow band imaging for Extensive Gastric Intestinal Metaplasia diagnosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Intestinal Metaplasia</condition>
  <arm_group>
    <arm_group_label>Targeted biopsy within Sydney Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.&#xD;
All tissues will be sent to immunohistochemistry as a gold standard.&#xD;
Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Targeted biopsy within Sydney protocol</intervention_name>
    <description>Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.</description>
    <arm_group_label>Targeted biopsy within Sydney Protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 year of age&#xD;
&#xD;
          -  Suspected GIM by previous tissue pathology&#xD;
&#xD;
          -  Able to provide informed consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous gastric surgery including gastrectomy and bypass surgery&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active upper GI bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rapat Pittayanon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Chulalongkorn Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rapat Pittayanon, MD</last_name>
    <phone>66804224999</phone>
    <email>rapat125@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natee Faknak, MD</last_name>
    <phone>66872006828</phone>
    <email>F.natee30@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rapat Pittayanon, MD</last_name>
    </contact>
    <contact_backup>
      <email>rapat125@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Rapat Pittayanon</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

